Repligen Corporation (RGEN)

NASDAQ: RGEN · IEX Real-Time Price · USD
192.71
+0.92 (0.48%)
At close: Feb 27, 2024, 4:00 PM
194.74
+2.03 (1.05%)
After-hours: Feb 27, 2024, 5:44 PM EST
0.48%
Market Cap 10.70B
Revenue (ttm) 638.76M
Net Income (ttm) 41.58M
Shares Out 55.77M
EPS (ttm) 0.74
PE Ratio 260.42
Forward PE 107.86
Dividend n/a
Ex-Dividend Date n/a
Volume 440,936
Open 190.86
Previous Close 191.79
Day's Range 189.50 - 194.98
52-Week Range 110.45 - 211.13
Beta 1.04
Analysts Strong Buy
Price Target 199.00 (+3.26%)
Earnings Date Feb 21, 2024

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput... [Read more]

Sector Healthcare
Founded 1981
Employees 1,783
Stock Exchange NASDAQ
Ticker Symbol RGEN
Full Company Profile

Financial Performance

In 2023, Repligen's revenue was $638.76 million, a decrease of -20.31% compared to the previous year's $801.54 million. Earnings were $41.58 million, a decrease of -77.64%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for RGEN stock is "Strong Buy." The 12-month stock price forecast is $199.0, which is an increase of 3.26% from the latest price.

Price Target
$199.0
(3.26% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f...

6 days ago - GlobeNewsWire

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET

20 days ago - GlobeNewsWire

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at th...

2 months ago - GlobeNewsWire

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreem...

2 months ago - GlobeNewsWire

UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of...

3 months ago - GlobeNewsWire

Repligen Announces Publication of the Company's 2022 Sustainability Report

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of...

3 months ago - GlobeNewsWire

Repligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting...

4 months ago - GlobeNewsWire

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of T...

4 months ago - GlobeNewsWire

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its t...

4 months ago - GlobeNewsWire

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same...

4 months ago - Market Watch

Repligen to Report Third Quarter 2023 Financial Results

Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET

4 months ago - GlobeNewsWire

Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ ...

5 months ago - GlobeNewsWire

Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova

WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into ...

5 months ago - GlobeNewsWire

Repligen Corporation to Present at Wells Fargo Healthcare Conference

WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presentin...

6 months ago - GlobeNewsWire

Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification

WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF u...

6 months ago - GlobeNewsWire

Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year

7 months ago - GlobeNewsWire

Repligen to Report Second Quarter 2023 Financial Results

Webcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET

7 months ago - GlobeNewsWire

Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi...

10 months ago - GlobeNewsWire

Repligen to Report First Quarter 2023 Financial Results

Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET

11 months ago - GlobeNewsWire

Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum

WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt...

1 year ago - GlobeNewsWire

Repligen Reports Fourth Quarter and Full Year 2022 Financial Results

WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f...

1 year ago - GlobeNewsWire

Repligen Appoints Martin D. Madaus to Board of Directors

WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus.

1 year ago - GlobeNewsWire

Repligen to Report Fourth Quarter and Full Year 2022 Financial Results

Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST

1 year ago - GlobeNewsWire

Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at th...

1 year ago - GlobeNewsWire

Is Repligen a Value Trap or a Value Opportunity?

The past 14 months have disappointed many shareholders of Repligen Corp. ( RGEN , Financial). Its price fell from $324.21 on Sept.

1 year ago - GuruFocus